August 9, 2021 7:37am

After a sloppy week and Friday’s my covered sector’s end barely positive; what bodes this week – more of same?

New market records have been reached and, I’m still a BYE-BYE man

Earnings’ releases today: Athersys (ATHX), bluebird bio (BLUE), Precigen (PGEN), Regenxbio (RGNX),

Pre-open indications: 2 BUYs; 2 SELLs: 2 SELLs into Strength; 1 Maintain SELL (see below)

My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

There is no breadline for fact and numbers-based share pricing intelligence!

Dow futures are DOWN -0.28% (-100 points), S&P futures are DOWN -0.013% (-9 points) and NASDAQ futures are UP +0.19% (+28 points)

 

Stock futures traded fluctuated lower on Monday projecting a o0ssible negative open,

European stocks were lower,

Asia-Pacific markets traded higher with indexes in Australia, Hong Kong and the Chinese mainland posting gains.

 

Henry’omics:

Not lookin’ good, weakness depreciates the open and possibly the morning session …

This a.m.’s futures trading follows the Dow rising 144.26 points, or +0.4%, to close Friday at an all-time high of 35,208.51, the S&P 500 rose +0.17% to reach its own record close of 4,436.52 and the Nasdaq dipped -0.4% to 14,835.76.

All three major indexes saw their second positive week in three.

 

Data Docket: Investors are awaiting key inflation data scheduled for release this week. The consumer price index I released Wednesday and the producer price index are scheduled for Thursday.

 

Thursday’s evening’s recap: “Back from the morning’s brink, safety is managing risk. The cell and gene therapy sector struggled for direction, all week long as earnings (see list) shaped the week” … https://www.regmedinvestors.com/articles/12038

  • The Nasdaq closed DOWN -59.35 points (-0.40%);
  • The IBB closed down -1.56% and XBI closed down -1.74%
  • Sector volume was LOW with 7 of the 18-upside having higher than the 3-month average 1volume with very LOW volume of 1 of 16-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was down -1.13 points or -6.54% at 16.15;
  • Friday’s percentage (%) of the 18-upside were +0.32% (MDXG) to +9% (RENE.L) while the 16-downside -0.08% (BLFS) to -5.73% (AXGN);

 

Q3/21:

  • August: 3 positive and 2 negative close
  • July: 6 positives, 1 holiday and 15 negative closes

Q2/21:

  • June: 15 positive and 8 negative closes
  • May:  8 positive, 12 negative closes and 1 holiday
  • April: 11 negative and 10 positive closes

Q1/21:

  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday

 

 

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542  … to date:

Net Income:

  • CRISPR Therapeutics (CRSP);
  • uniQure NV (QURE);

Net losses:

  • Ultragenyx Pharmaceuticals (RARE);
  • Verastem (VSTM)
  • Alnylam Pharmaceuticals (ALNY);
  • Sage Therapeutics (SAGE);
  • Global Blood Therapeutics (GBT)
  • MiMedx (MDXG)
  • Ionis Pharmaceuticals (IONS);
  • Editas Medicine (EDIT);
  • Vericel (VCEL);
  • Brainstorm Cell Therapeutics (BCLI);
  • Intellia Therapeutics (NTLA);
  • Caladrius Biosciences (CLBS);
  • Sangamo Therapeutics (SGMO);
  • Adverum Biotechnologies (ADVM);
  • Cellectis SA (CLLS);

 

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) Chronicles - Maintaining Sell – notice how the shares trade with and without being “pumped”?

Biostage (BSTG) closed up +$0.05 on Friday with 709 shares traded after Thursday with 5 shares traded, Wednesday with 50 shares traded, Tuesday’s flat with 616 shares traded following last Monday’s -$0.05 to $1.60 with 571 shares traded.

Question#1: WHAT is the end game or play-book for this company, it has NOT done ANYTHING to monetize their asset of an approved IND with NO clinical trial initiative … so WHERE and WHAT is the value proposition?

MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.

 

Pre-open Indications:

SELL into Strength:

Editas Medicine (EDIT), CRISPR Therapeutics (CRSP),

 

SELL:
Sage Therapeutics (SAGE), Intellia Therapeutics (NTLA),

 

BUY:

bluebird bio (BLUE), Cellectis SA (CLLS)

 

The BOTTOM LINE:

I was skittish over Friday; today, I am just NERVOUS on Monday, that doesn't seem to be taking shape – re direction.

The cell and gene therapy sector has experience dramatic upside move and downside putting a real edge on share pricing as earnings continued to guide sector sentiment … following last week’s seventeen (17) releases to date.

Q2 earnings potential LPS (loss-per-share): this week

  • Earnings’ releases today: Athersys (ATHX), bluebird bio (BLUE), Precigen (PGEN), Regenxbio (RGNX),
  • BioLife Solutions (BLFS) – 8/12

Remember: Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out.

Risk is no doubt increasing as we head into the troublesome August and September months

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

My motto, never leave an investor uninformed about what I know!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.